X0306 4 2020-12-01 0 0001746473 PLIANT THERAPEUTICS, INC. PLRX 0001809204 Cummings Keith Lamont C/O PLIANT THERAPEUTICS, INC. 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Financial Officer Common Stock 2020-12-01 4 M 0 11591 2.08 A 34712 D Common Stock 2020-12-01 4 M 0 7143 6.22 A 41855 D Common Stock 2020-12-01 4 S 0 1139 28.24 D 40716 D Common Stock 2020-12-01 4 S 0 1848 29.07 D 38868 D Common Stock 2020-12-01 4 S 0 14901 30.21 D 23.967 D Common Stock 2020-12-01 4 S 0 846 30.72 D 23121 D Stock Option (right to buy) 2.08 2020-12-01 4 M 0 11591 0.00 D 2029-01-23 Common Stock 11591 194597 D Stock Option (right to buy) 6.22 2020-12-01 4 M 0 7143 0.00 D 2030-03-30 Common Stock 7143 35698 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.63 to $28.61, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.675 to $29.655, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.685 to $30.65, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.698 to $30.775, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4. 25% of the shares subject to such option vested on December 31, 2019 and 1/48th of the shares subject to the option vest in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date. Exhibit 24 - Power of Attorney /s/ Mike Ouimette, attorney-in-fact 2020-12-02